For a significant portion of his career, Arnold Levinson, PhD, MJ, has done work related to cancer.
Rachel Sauer
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Patient Care Community Immunotherapy lymphoma ColoradoSPH at CU Anschutz
For a significant portion of his career, Arnold Levinson, PhD, MJ, has done work related to cancer.
Research Community Cancer ColoradoSPH at CU Anschutz
There’s a growing body of research supporting the satisfactions of gardening, from its positive impact as a mental health intervention to its association with improvement in cognitive function and reduction in stress, anger, and fatigue.
Community Colorectal Cancer ColoradoSPH at CU Anschutz
Earlier this month, medical professionals, patient advocates, industry innovators, federal policymakers, and public health officials, including two members of the University of Colorado Cancer Center, gathered at the White House for the Cancer Moonshot Colorectal Cancer Forum.
Community Cancer Magazine Equity Diversity and Inclusion ColoradoSPH at CU Anschutz Leadership
Two important numbers to keep in mind are that 50.5% of the U.S. population is female, and that cancer will account for more than 606,000 deaths in the United States this year, making it the second-leading cause of death.
Research Community Cancer ColoradoSPH at CU Anschutz
In the course of her research studying employment and cancer, Cathy J. Bradley, PhD, MPA, deputy director of the University of Colorado Cancer Center, has heard from people diagnosed with cancer who would skip a chemotherapy treatment rather than skip work and risk losing their job.
Press Releases Community ColoradoSPH at CU Anschutz Leadership
Jan Lowery, PhD, MPH, who started her career as a researcher at the University of Colorado Cancer Center, returned September 1 as assistant director for dissemination and implementation for the Office of Community Outreach and Engagement at the CU Cancer Center. In her new role, Lowery will lead efforts to develop, conduct, and disseminate implementation-focused projects in cancer prevention, early detection, and survivorship.
Research Community ColoradoSPH at CU Anschutz
A cancer diagnosis can be difficult to work through in the best of circumstances, but factor in barriers related to language, insurance status, educational achievement, geographic location, income level, and more, and the cancer journey — everything from prevention and screening to diagnosis and treatment — can become nearly impossible to traverse.
Equity Diversity and Inclusion ColoradoSPH at CU Anschutz
April has been designated National Minority Cancer Awareness Month to bring attention to the health disparities that lead to higher rates of cancer in Black, Hispanic, American Indian/Alaskan Native, and other communities of color.
Research Community Faculty Equity Diversity and Inclusion ColoradoSPH at CU Anschutz
While conducting research for her doctoral dissertation, Channing Tate, PhD, MPH, spoke with 144 older Black adults about hospice care – what they knew about it, whether they’d consider it, what their experiences with hospice had been.
Research Lung Cancer ColoradoSPH at CU Anschutz
Genetically targeted drugs and immunotherapies are transforming the way we treat many forms of lung cancer. However, a University of Colorado Cancer Center study published in the Journal of the National Cancer Institute shows that while the use of these drugs rose 27 percent from 2007 to 2015, new, high-cost lung cancer drugs are not used equally in all places, with all patients. Patients who lived in high-poverty areas were 4 percent less likely to be treated with high-cost lung cancer drugs. On the other hand, patients treated at National Cancer Institute-designated cancer centers were 10 percent more likely to be given these drugs than were patients treated in other settings.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.